A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma

[1] Fisher RI(1993)Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma N Engl J Med 328 1002-1006

[2] Gaynor ER(1995)Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma N Engl J Med 333 1540-1545

[3] Dahlberg S(1988)Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) Blood 71 117-122

[4] Oken MM(1991)Treatment of relapsed non-Hodgkin’s lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation J Clin Oncol 9 423-431

[5] Grogan TM(1997)Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience Hematol Oncol Clin North Am 11 937-947

[6] Mize EM(1994)ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study J Clin Oncol 12 1169-1176

[7] Glick JH(1994)E-SHAP: an effective treatment in selected patients with relapsed non-Hodgkin’s lymphoma Ann Oncol 5 453-456

[8] Coltman CA(1999)Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma J Clin Oncol 17 3776-3785

[9] Miller TP(1998)Oxaliplatin: mechanism of action and antineoplastic activity Semin Oncol 25 4-12

[10] Philip T(1996)Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel Biochem Pharmacol 52 1855-1865

[1] Fisher RI(1993)Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma N Engl J Med 328 1002-1006

[2] Gaynor ER(1995)Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma N Engl J Med 333 1540-1545

[3] Dahlberg S(1988)Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) Blood 71 117-122

[4] Oken MM(1991)Treatment of relapsed non-Hodgkin’s lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation J Clin Oncol 9 423-431

[5] Grogan TM(1997)Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience Hematol Oncol Clin North Am 11 937-947

[6] Mize EM(1994)ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study J Clin Oncol 12 1169-1176

[7] Glick JH(1994)E-SHAP: an effective treatment in selected patients with relapsed non-Hodgkin’s lymphoma Ann Oncol 5 453-456

[8] Coltman CA(1999)Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma J Clin Oncol 17 3776-3785

[9] Miller TP(1998)Oxaliplatin: mechanism of action and antineoplastic activity Semin Oncol 25 4-12

[10] Philip T(1996)Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel Biochem Pharmacol 52 1855-1865